Impact of Adipose Tissue Repartition on the Time Course of Vascular Dysfunction - the NUMEVOX Cohort

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2009 by University Hospital, Angers
Information provided by:
University Hospital, Angers Identifier:
First received: October 16, 2009
Last updated: NA
Last verified: October 2009
History: No changes posted
The NUMEVOX cohort is intended to follow-up the macro and microvascular dysfunction in relation to adipose tissue repartition in patients with metabolic syndrome associated to liver steatosis, sleep apnea. Duration of the follow-up is 3 years for each patient entering the cohort.

Metabolic Diseases
Sleep Apnea

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Impact of Adipose Tissue Repartition on the Time Course of Vascular Dysfunction - the NUMEVOX Cohort

Resource links provided by NLM:

Further study details as provided by University Hospital, Angers:

Biospecimen Retention:   Samples With DNA
serum and DNA

Estimated Enrollment: 500
Study Start Date: March 2008
Estimated Study Completion Date: March 2017
Estimated Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Metabolic syndrome (MS)
Patients suspected of metabolic syndrome without sleep apnea or liver steatosis
MS with sleep apnea
Metabolic syndrome with sleep apnea
MS with Liver steatosis
Metabolic syndrome with liver steatosis


Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Any patient suspected of metabolic syndrome with or without sleep apnea or liver steatosis.

Informed consent with signature.


Inclusion Criteria:

  • informed consent
  • age > 18 years old
  • suspected of metabolic syndrome
  • affiliated to french social health care

Exclusion Criteria:

  • age < 18 years old
  • pregnancy
  • no informed consent
  • not eligible for the study (no MS, cancer)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00997165

Contact: PIERRE HENRI DUCLUZEAU, MD PhD 33(0)663384160
Contact: GEORGES LEFTHERIOTIS, MD-PHD 33(2)41-35-44-56

Pôle Maladies Métaboliques et Médecine Interne Recruiting
Angers, France, 49993
Sub-Investigator: GEORGES LEFTHERIOTIS, MD-PHD         
Sub-Investigator: FREDERIC GAGNADOUX, MD-PHD         
Sub-Investigator: PAUL CALES, MD-PHD         
Sponsors and Collaborators
University Hospital, Angers
Study Director: pierre henri Ducluzeau, MD PhD UH Angers
  More Information

No publications provided

Responsible Party: Pierre Henri Ducluzeau/MD-PhD, UH Angers Identifier: NCT00997165     History of Changes
Other Study ID Numbers: CHU-Promoteur 08-01
Study First Received: October 16, 2009
Last Updated: October 16, 2009
Health Authority: France: Ministry of Health

Keywords provided by University Hospital, Angers:
fatty liver
adipose tissue

Additional relevant MeSH terms:
Metabolic Diseases
Arterial Occlusive Diseases
Cardiovascular Diseases
Vascular Diseases processed this record on November 27, 2015